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Soft tissue sarcomas (STS) are a group of rare and heterogenous cancers, that diverse a
wide spectrum of histology and varied clinical behavior. The aim was to study, retro-
spectively and prospectively the adverse effects of therapy in STS patients attending the
Pediatric Oncology Clinic, National Cancer Institute (NCI), Cairo University during the last
10 years. Files of 106 STS patients were revised for history, staging, investigations, treat-
ment modalities and side effects of therapy. Radiotherapy (RTH) and surgery remains the
backbone of the multi-modality treatment plan. Chemo-radiotherapy (CRTH) induces acute
and delayed toxicity in the form of hematological & gastrointestinal (GIT) toxicity and al-
opecia that occur in all patients. However, hepatic & genitourinary toxicity, cardiotoxicity,
neurotoxicity and skin complications can be seen in 13.2%, 11.3%, 1.9% and 4.7% and 28.3%
of patients respectively. Mucositis was noticed in 42.5% of patients, 15.1% of themwere due
to RTH, which can also cause dysphagia & dysphonia, impaired taste sensation and tran-
sient conjunctivitis in 4.7%, 1.9% and 6.6% of patients respectively. Additionally, 46.7% of
post-pubertal patients were found to be azoospermic >5 years of end of treatments.
However, 3.8% and 6.6% of patients developed ototoxicity and skin fibroses due to local
irradiations. Furthermore, hypo- or hyperthyroidism and growth retardation was
encountered in 7.5% and 6.6% of patients respectively. However, 5.7% of patients developed
secondary malignancy, 7 years after the end of CRTH.
Finally, the current study concluded that STS multidisciplinary management may cause
early and late toxicity. Future approaches including radiation dose and volume reduction
or application of new radiation technologies are needed. New strategies with reduction or
elimination of chemotherapy (CTH) dose are also recommended for dealing with pediatric
STS patients.
Copyright © 2015, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Soft tissue sarcoma (STS) constitutes a heterogenous group of
rare cancers, with heterogenous clinical presentation, histo-
logical subtypes and molecular alterations (Blay et al., 2013).
Therefore, its management requires an experienced multi-
disciplinary team in an expert center (Faivre, & Le Pechoux,
2013). They constitute about 1% of all solid tumors, (Shukla
& Deo, 2011) and can occur in any part of the body (Umer,
Umer, Qadir, Abbasi, and Masood, 2013). It present most
commonly as an asymptomatic mass, and swelling was the
presenting symptom in 96% patients (Shukla & Deo, 2011).
Their biological behavior is characterized by local aggres-
siveness and tendency to hematogenous spreading. Almost
50% of STS patients developmetastatic disease,mainly within
three years from initial diagnosis. The distribution of metas-
tases from STS varies, depending on the primary site and
histological subtype (Vincenzi et al., 2013). The prognosis of
STS is determined by histological subtype, tumor size, locali-
zation, grade and the presence of metastases (Jakob, Rauch,
Wenz, and Hohenberger, 2013). In pediatric oncology, most
treatment concepts in the 21st century are of curative intent,
aiming at long-term overall survival (OS) (Combs et al., 2012).
The goals of sarcoma management include both a cure and
functional preservation of involved tissues and adjacent crit-
ical structures (Kandel et al., 2013).With the advancesmade in
the fields of imaging, surgical, medical and radiation oncology
along with better understanding of tumor pathology and
biology more effective management protocols are currently
available (Shukla & Deo, 2011). Treatment are often multi-
modal and complex, and patients can experience significant
morbidity and mortality as a consequence of treatment or the
disease (Kandel et al., 2013). The standard treatment protocol
involves wide surgical resection along with neoadjuvant or
adjuvant RTH (Umer et al., 2013). The mainstay of therapy of
non-metastasized STS is complete surgical resection com-
bined with irradiation in large, high-grade tumors which are
located deep to the superficial body fascia (Jakob et al., 2013).
The application of brachytherapy (BRT) as a complementary
therapy in STS has a history of 30-years. BRT seems to be a
good method of adjuvant therapy in extremity STS, however
its accessibility is limited. The number of complications was
small. Further multicentre randomized studies should decide
whichmethod of adjuvant treatment (external beam radiation
therapy (EBRT) vs. BRT) is better and what is the optimal
sequence of therapies improving local control (Guzik, Lyczek,
and Kowalik, 2012). The established standard of care for
unresectable STS in first line is doxorubicin-based CTH, with
typical response rates ranging from 10% to 30%. For patients
who relapse or develop resistance, other therapeutic options
were limited before the availability of trabectedin. For these
patients, progression-free survival (PFS) and OS rarely exceed
6 months and 1 year respectively (Blay et al., 2013).
With continuous increase in tumor control and cure, also
side effects of the treatments, especially long-term side ef-
fects, have moved even more into focus (Combs et al., 2012).
Examples are cardiac toxicity from anthracyclines, hearing
loss or tinnitus from cisplatin, infertility from alkylator ther-
apy or radiation to the pelvis, endocrine complications usuallyfrom radiation to reproductive organs or the hypothalamic-
pituitary axis, bladder dysfunction from CTH and radiation,
and secondmalignant neoplasms due to radiation and/or CTH
(Arndt, Rose, Folpe, and Laack, 2012; Ginsberg, Goodman, and
Leisenring, 2010; Nagarajan, Kamruzzaman, and Ness, 2011).
Furthermore, thrombocytopenia (TCP) is a common side effect
of CTH, and multiple studies have suggested that
Chemotherapy-induced thrombocytopenia (CIT) is a dose-
limiting adverse event (AE) in the treatment of cancer, and
can necessitate dose delays and/or dose reductions (Chawla
et al., 2013). On the other hand, children receiving platinum-
compound CTH for the treatment of malignancies may be at
risk of an early- or delayed-onset hearing impairment that
may affect learning, development, communication, school
performance, social interaction and overall quality of life (Nitz
et al., 2013; Orgel et al., 2012; PecoraLiberman et al., 2011;
Skinner, 2004). However, port-associated complications (par-
avasation, irritation, infection) weremore frequent (13%) than
in continuous infusion protocols with other drugs (e.g., 5-FU)
administered in the large outpatient center (Hoiczyk et al.,
2013). With respect to RTH, sparing of normal tissue and
reduction of integral dose is the most effective means to
prevent treatment-related side effects. Over the last decades,
advances in radiation oncology from conventional 2D-to 3D-
radiation therapy, to the establishment of high-precision
stereotactic RTH and subsequently intensity-modulated
radiotherapy (IMRT) have continuously enabled the radiation
oncologist to deliver higher local doses even to complex target
volumes while sparing surrounding organs at risk (OAR).
However, intermediate and low doses of radiation remain to
be applied. One way of reducing integral dose and potentially
reducing side effects is the use of particle therapy, due to the
physical properties of ion beams (Combs et al., 2012).
Although the introduction of multimodal treatment of STS
improved local tumor control, local failure still occurs in a
good number of patients. Therefore, further improvement of
current treatment strategies is necessary (Jakob et al., 2013).
The aim of the present work is to retrospectively and pro-
spectively study the adverse effects of therapy in STS patients
attending the Pediatric Oncology Clinic, National Cancer
Institute (NCI), Cairo University during the last 10 years (from
January 2004 till January 2014).2. Patients and methods
One hundred and six STS patients were recorded among the
total pediatric malignant cases registered during the period of
study. Data were collected about age of the patients at pre-
sentation, sex, primary site (s), staging, histopathological
subtype, site of metastases (if present) and dose & duration of
therapy. Clinical examinations were done laying stress on site
and clinical extent of tumor with assessment of nodal
enlargement. Results of routine laboratory investigations;
bone marrow aspiration and/or biopsy were also reviewed.
The results of plain X-ray, CT scans or MRI, isotopic bone scan
for evaluations of the primary site and metastasis. Scrotal
sonography for paratesticular tumor was also identified. Uri-
nalysis and assessment of bladder function by cysto-
urethrogram in case of hemorrhagic cystitis. Follow-up was
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months for first 2 years, every 6 months thereafter during 3
years, and then annually. Times of follow-up were measured
from the date of diagnosis.
The studied patients included 70 (66%) males and 36 (34%)
females, with a male to female ratio of 1.94:1. Their ages
ranged from 6 month to 21 years with a mean of 9 ± 5.8 years
and median age of 9 years. 64 (60.4%) of the patients were
below 10 years old. The follow-up time for all patients ranged
from 5 to 80 months with median of 38 months. Staging was
done according to IRS-TNM pretreatment clinical staging
classification and IRS clinical grouping classification (Dalen
et al., 2004; Wunder, Healey, Davis, and Brennan, 2000). CT
guided or open surgery biopsy was done to confirm the di-
agnoses and to define the histological subtypes.Table 1 e Clinical characteristics of STS patients.
Items No % Items No %
Age: Sex:
- <10 years 64 60.4 - Male 70 66
- >10 years 42 39.6 - Female 36 34
Tumor size: Metastasis:
>5 cm 73 68.9 Present 6 5.7
<5 cm 33 31.1 Absent 100 94.32.1. Treatment modalities
2.1.1. Surgery
Initially, a wide and complete resection of the primary tumor
with a surrounding envelope of normal tissue was done, fol-
lowed by second look operation according to need. Delayed
resection of the primary tumor was performed at week 12
evaluation for local control. Delayed resection of the residual
primary tumor after RTH is recommended to achieve com-
plete remission and to improve the accuracy of clinical and
radiological assessment of response.
2.1.2. Radiotherapy
Patients received RTH according to their stage and clinical
group.
All patients received RTH at week 12e13 except node
negative, completely resected patients, and patientswho have
had second look resection. Patients with parameningeal sites
with criteria of meningeal extension and who require emer-
gency RTH begin RTH at day zero. RTH was given for all
microscopic and gross residual with entire lymph node in-
volvements and to all sites of metastatic disease which can be
localized and imaged (i.e. excluding the bone marrow).
Treatment is directed to the initial tumor volume in all
cases with 2e3 cm safety margins. Conformal 3D planning is
performed to decrease the dose to normal tissuewithminimal
radiation dose to the ossific center in children. Oophropexy
marked by metal clips was done in pelvic irradiation in girls,
and external lead shield in boys. Megavoltage conventional
daily fractionation was given in a dose of 45 GY in 25 daily
fractions (1.8 GY/fraction, to be reduced to 1.5 GY for large
sensitive volumes). A boost of 5 GY in 3 daily fractions was
used according to the site, and increased to 10 GY in 6 daily
fractions with residual microscopic disease. Furthermore,
without skull base erosion and cranial nerve palsy, the brain,
skull base and meninges are not routinely irradiated.
2.1.3. Chemotherapy
Patients received VAC regimen for 40e47 weeks according to
the grades of the disease:
- Vincristine (V): 1.5mg/m2 (max 2mg) IV push. In patient <1
year as 0.025 mg/kg IV push.- Actinomycin D (A): 0.45 mg/kg (max 2.5 mg) IV push. In
patient <1 year as 0.025 mg/kg IV push. Or can be given
as1.35 mg/m2 IV push High risk patients.
- Cyclophosphamide (C): 1.2 mg/m2 IV infusion over 60
mints with hydration and Mesna. In patient <1 year as
40 mg/kg. It can be given as 1.5e1.8 mg/m2 IV infusion over
2 h with hydration and Mesna in High risk patients.2.1.4. Statistical analysis
Statistical analysis was done using Statistical Package for
Social Sciences (SPSS). Mean, standard deviation, percentage,
and Chi-square was applied whenever indicated. Survival
analysis; including OS, DFS were done. Differences between
groups were tested for statistical significance using log rank
test. P value was always two-tailed and is significant at
p  0.05 (Winters, Winters, and Amedee, 2010).3. Results
The results of the present work are presented in Tables (1e7)
and in Figure (1e4).
Most of patients presented below 10 years old with male
predominant (66%) (Table 1). STS originated from the head
and neck in most of patients 38 (35.8%) [Parameningeal 17
(16%), orbital 11 (10.3%), and others 10 (9.5%)], followed by
Extremity 27 (25.5%) then Genitourinary 19 (17.9%) and
Retroperitoneal 12 (11.3%) respectively (Table 1, Fig. 1). The
predominant subtype of STS was Embryonal (61.3%) followed
by Alveolar subtype (21.8%) then other types (Table 1, Fig. 2).
The presenting stage of the disease was stage III 65 (61.3%)
followed by stage I 23 (21.7%) then II 12 (11.3%) and IV 6 (5.7%)
respectively (Table 1, Fig. 3).
Nearly 69.8% of the patients received RTH with or without
CTH and 43.4% of them have been resected for the primary
tumor (Table 2).
At the end of treatment, complete remission (CR) was
achieved in92 (86.8%) of patients. Meanwhile, 8 (7.5%) of cases
had disease progression and 5.7% died (Table 3). The 2-years
OS was 80.2% (Table 3). However, the 2-years and 5-years
DFS were 65.1% and 56.6% respectively. Moreover, 16 (15.1%)
and 25 (23.6%) of patients relapsed >2 years and 5 years after
the end of treatment. The rest of the patients 57 (69.5%) ach-
ieved local control.
Acute Toxicity of Chemo-Radiotherapy in the present
study resembled in Tables (4e6) and Figure (4): According to
Common Toxicity Criteria (adopted in SIOP Trial) patients can
Table 2 e Treatment modalities in the studied group.
Type No. % Total %
Radiotherapy: 74 69.8
Radiotherapy alone 27 25.5
Chemo-radiotherapy 47 44.3
No radiotherapy 32 30.2
Radiotherapy doses
36 GY 25 23.6
41.40 GY 45 42.5
45 GY 16 15.1
50.40 GY 15 14.1
59.60 GY 5 4.7
Surgery: 46 43.4
Initial surgery 48 45.3
Delayed surgery (at w12) 32 30.2
Biopsy alone 23 21.7
Surgery at the end 3 2.8
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also, Alopecia were seen in all patients. The use of G-CSF is
highly statistically significant regarding anemia and
neutropenia (P-value was 0.0041 and 0.0036 respectively).
Elevated liver enzymes were reported in 14 (13.2%) of patients
with detection of hepatitis C viral infection in 7 (6.6%) of them.
Twelve patients (11.3%) developed Cyclophosphamide
induced hemorrhagic cystitis. All of them showed marked
improvement with dose reduction and continuous Mesna
infusion. Peripheral neuritis grade 2 was reported in 4 (3.8%)
patients following week 3. Vincristine was withheld in this
patient for the remaining courses. Only one patient (0.9%)
with nasopharyngeal mass and extensive intracranial
component developed convulsions following week 4.
Skin complicationswere observed in 30 (28.3%) of patients.
20 (18.9%) of them were complaining of erythema grade I, 5
(4.7%) with dry desquamation, and 5 (4.7%) with wet desqua-
mation due to RTH. One patient from the wet desquamation
group occurs in the previously irradiated field following Acti-
nomycin D. Among the 38 cases of head and neck tumor 25
(23.6%) cases received RTH. Sixteen cases (15.1%) of whom
received RTH developed mucositis, 9 (8.5%) of them were
grade 3. However, dysphagia and dysphonia were reported in
5 (4.7%) cases and impaired taste sensation in 2 (1.9%) cases
only. Additionally, among the 9 (8.5%) cases that received
orbital irradiation 7 (6.6%) of them developed transient
conjunctivitis that improved with medications. On the other
hand, among the 31 (29.2%) pelvi-abdominal site patients, 20
(18.9%) cases received RTH, 9 (8.5%) cases of them developed
grade 2 diarrhea and vomiting (Fig. 4).Table 3 e Response of STS patients to protocols of therapy.
Response to therapy At the end of
treatment
NO %
Complete remission(CR) 92 86.8
Progressive disease (PD) 8 7.5
Death 6 5.7
Total 106 100Surgical Complications: Definitive surgery was instituted
in 46 cases. Only 2 cases reported surgical complications. The
1St one was 1.5 years old female with extremities STS. She
developed severe skin infection with skin necrosis that ne-
cessitates repeated dressing and antibiotic therapy for 3
weeks. The 2nd case was 16 years old female with chest wall
PNET. She was subjected to excision of the lesion with the
related ribs with reconstruction using synthetic mesh. She
developed postoperative infection around the mesh that ne-
cessitates second look operation to remove the mesh 3
months later.
Delayed complications: This can be seen 5 years or more
after the end of treatment. Semen analysis was done in 15
patients who were >16 years old 5 years after the end of
treatment, 7 of them 7/15 (46.7%) were found to be azoosper-
mic. Four (3.8%) patients developed ototoxicity due to local
irradiations, one of them with external ear primary tumor.
However, skin fibrosis was seen in 6.6% of patients. Further-
more, Hypo- and hyperthyroidismwas encountered in 8 (7.5%)
of patients and growth retardation was seen in 7 (6.6%). One
patient only developed urinary complications in the form of
artificial bladder and urinary diversion due to radical cys-
tectomy for bladder mass. However, 6 (5.7%) of patients
developed secondary malignancy, 7 years after the end of
CRTH (Table 7).4. Discussion
The management of STS has evolved over last two decades
with the advances made in the fields of imaging, histopa-
thology, molecular biology, cytogenetic and multimodality
management (Shukla & Deo, 2011). Multimodal treatment of
STS with CTH and irradiation has been introduced in the
1970s. Radiation may be administered preoperatively or
postoperatively (Jakob et al., 2013). Effective risk-based ther-
apy for the management of childhood cancer in the setting of
clinical trials has been the cornerstone of the tremendous
progress in OS seen over the last four decades, with 5-year
survival rates now at 80% (Landier & Bhatia, 2008). This was
comparable with the current study where CR was achieved in
86.8% of patients and the 2-years OS was 80.2%. However, the
2-years and 5-years DFS were 65.1% and 56.6% respectively.
Moreover, 69.5% of the patients achieved local control.
Dose-intensive CTH has become routine for the treatment
of most pediatric sarcomas because CTH dose-intensity cor-
relates with tumor response and outcome. Neutropenia is a
common toxicity of these regimens (Ferrari et al., 2005; GrierAfter 2 years of
treatment
After 5 years of
treatment
NO % NO %
85 80.2 82 77.4
0 0 0 0
21 19.8 24 22.6
106 100 106 100
Table 4 e Acute toxicity after chemo-radiotherapy treatment of STS.
Acute toxicity No. % Acute toxicity No. %
Hematological toxicity: GIT:
Leucopenia 80 75.5 Nausea & vomiting 94 88.7
Neutropenia 76 71.7 Diarrhea 36 34.0
Anemia 83 78.3 Oral complications 45 42.5
Thrombocytopenia 38 35.8
Cardiotoxicity 2 1.9 Hepatic toxicity 14 13.2
Use of G-CSF: Genitourinary:
Given 15 14.2 Bladder 12 11.3
Not given 91 85.8 Nephrotoxicity 0 0
Infection (Febrile neutropenia) 76 71.7 Neurotoxicity 5 4.7
Skin complications 30 28.3 Alopecia 106 100
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nadir and duration of severe neutropenia influence the
development of infectious complications. Therefore, pre-
venting or shortening the duration of neutropenia following
CTHmay facilitate dose-intensity, improve safety, and control
costs (Spunt et al., 2010). In the current study, Hematological
toxicity was seen in all patients, 71.7% of them were neu-
tropenic and develop febrile neutropenia (FN). However, 42.5%
of neutropenic patients were grade 4. Furthermore, Anemia,
leucopenia, and TCP were developed in 78.3%, 75.5%, and
35.8% of patients respectively. Additionally, the use of growth
factors was needed in 14.2% of patients with improving in the
hematological picture. The result is highly statistically sig-
nificant regarding anemia and neutropenia (P-value was
0.0041 and 0.0036 respectively). Thrombocytopenia (TCP) is a
common treatment-related Grade 3/4 AE and dose-limiting
toxicity for various CTH regimens (Ang et al., 2009; Blay
et al., 2008; Hensley et al., 2009; Kantarjian et al., 2010).
Doxorubicin and ifosfamide, alone and in combination (AI),
are active in the treatment of STS, with demonstrated positive
response rates and improvements in OS; however, both
agents have been associated with Grade 3/4 TCP that is cu-
mulative with successive CTH cycles (Chawla et al., 2013;
Lashkari et al., 2009; Maurel et al., 2009; Sleijfer et al., 2010;
Tascilar, Loos, Seynaeve, Verweij, and Sleijfer, 2007; Worden
et al., 2005). CIT may lead to dose reductions or dose delays,
resulting in less than optimal disease control. In severe cases,
CIT may result in hemorrhage and a need for platelet trans-
fusions, which have cost and safety limitations (Chawla et al.,
2013; Lashkari et al., 2009; Maurel et al., 2009; Schiffer et al.,
2001; Worden et al., 2005). Growth factor use, results in a
relative decrease in the incidence of rather than absolute
prevention of FN (Spunt et al., 2010). However, Randomized
clinical trials in both children and adults have demonstrated
that filgrastim prophylaxis for CTH-induced neutropeniaTable 5 e Hematological toxicity in STS patients.
Hematological toxicity Grade 0 Grade 1
No. % No. %
Leucopenia 26 24.5 10 9.5
Neutropenia 30 28.3 8 7.5
Anemia 23 21.7 26 24.5
Thrombocytopenia 68 64.2 8 7.5results in reduction of duration of grade 4 neutropenia,
(Crawford et al., 1991; Trillet-Lenoir et al., 1993) number of
episodes of FN (Pettengell et al., 1992; Welte et al., 1996)
number and duration of hospitalizations, (Crawford et al.,
1991; Heil et al., 1997; Pui et al., 1997) number of docu-
mented infections, (Heil et al., 1997; Pui et al., 1997; Welte
et al., 1996) and use of antibiotics (Crawford et al., 1991;
Michon et al., 1998; Trillet-Lenoir et al., 1993; Welte et al.,
1996). Filgrastim use has become routine in the management
of pediatric sarcomas requiring CTH (Ferrari et al. 2005; Grier
et al., 2003; Spunt et al., 2010; Wexler et al., 1996). Although
interleukin-11 (IL-11), a hematopoietic growth factor with
thrombopoietic activity, is approved for the treatment of CIT
in the US, it is not approved in the EU, it has modest efficacy,
and it produces substantial adverse effects that limit its use
(Chawla et al., 2013; Vadhan-Raj, 2009). For example, a data-
base analysis of 47,159 patients with both solid tumors and
hematologic malignancies showed that TCP increased from
11% at baseline to 22e64% following CTH treatment (Wu,
Aravind, Ranganathan, Martin, and Nalysnyk, 2009). Grade 3/
4 TCP has been reported in 63% of patients with advanced STS
treated with AI CTH (Worden et al., 2005). In the current study
Grade 3/4 TCP was seen in 21.7% of patients. However, an
effective agent for the treatment of CIT may allow CTH
administration according to schedule andwithout dose delays
and/or reductions (Chawla et al., 2013).
A variety of radio-therapeutic approaches have been used
in the adjuvant localmanagement of STS. These include EBRT,
BRT, and intraoperative radiation therapy (Viani et al., 2008).
Unfortunately, radiation to soft tissues and bones within the
treatment field can lead to skeletal deformity and growth
retardation. Radiation to the thorax can result in pulmonary
fibrosis and cardiac dysfunction, and radiation to the pelvis
can result in infertility (Armstrong, Stovall, and Robison, 2010;
Arndt et al., 2012; Ginsberg et al., 2010). Sterzing et al. reportedGrade 2 Grade 3 Grade 4
No. % No. % No. %
15 14.1 16 15.1 39 36.8
9 8.5 14 13.2 45 42.5
28 26.4 20 18.9 9 8.5
7 6.6 13 12.2 10 9.5
Table 6 e Gastrointestinal and genitourinary toxicity in STS patients.
Item Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. % No. %
Oral mucositis 61 57.6 7 6.6 25 23.6 13 12.2 0 0
Nausea &vomiting 12 11.3 10 9.5 39 36.8 37 34.9 8 7.5
Diarrhea 70 66.0 10 9.5 14 13.2 12 11.3 0 0
Hepatic toxicity 92 86.9 9 8.5 3 2.8 1 0.9 1 0.9
Bladder toxicity 94 88.7 7 6.6 3 2.8 2 1.9 0 0
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spine irradiation. One adolescent, who was also treated with
CTH, claimed of hypoaesthesia in his right forearm, two years
after upper thoracic wall irradiation. In the present study,
azoospermia was seen in 46.1% of post-pubertal patients.
Hypo- and hyperthyroidism was encountered in 7.5% of pa-
tients and growth retardation was seen in 6.6%. Furthermore,
cardiotoxicity was observed in 1.9% and Peripheral neuritis
grade 2 was reported in 3.8% patients following week 3. Only
one patient (0.9%) with nasopharyngeal mass and extensive
intracranial component developed convulsions following
week 4 and it was attributed to the disease itself. However,
EBRT can cause growth retardation or adversely affect organ
function in the pediatric population (Viani et al., 2008). On the
other hand, Sterzing et al. reported acute side effects of RTH
were low grade skin erythema (grade I-II), mucositis (grade I-
II), local alopecia, mild nausea, mild diarrhea, loss of taste and
epistaxis. In the current study, skin complications were
observed 28.3% of patients. Nearly 18.9% of them were com-
plaining of erythema grade I, 4.7% with dry desquamation,
and 4.7% with wet desquamation due to RTH. One patient
from the wet desquamation group occurs in the previously
irradiated field following Actinomycin D. Additionally; skin
fibrosis was seen in 6.6% of patients. GIT toxicity (including
nausea, vomiting & diarrhea) and alopecia were seen in all
patients. Furthermore, mucositis, was noticed in 42.5% of
patients, 16 (15.1%) of them due to RTH. The incidence of
complications after antineoplastic therapy is increasing in
relation to the incidence of cancer and prolonged survival rate
(Kucharska, Negrusz-Kawecka, and Gromkowska, 2012).
Mucositis causes significant pain, chewing and swallowing
difficulties and is considered the most debilitating acute re-
action during cancer treatment (Rose-Ped et al., 2002; Schmidt
Santos, Dias, Giordani, Segreto, and Comodo Segreto, 2011).
Radiation affects the volume and production of saliva, as well
as its composition. Patients frequently describe thickened,
tenacious, ropy saliva, which may make speech difficult be-
sides affecting swallowing and taste. Additionally, skin re-
actions, in the form of skin tanning, dry desquamation andTable 7 e Delayed toxicity after chemo-radiotherapy treatmen
Delayed toxicity No. %
Gonadal dysfunction: 7/15 46.7
Ototoxicity: 4/106 3.8
Endocrinal problems: 15 14.2
Hypothyroidism 5 4.7
Hyperthyroidism 3 2.8
Impaired growth 7 6.6increased melanin production with telangiectasis are
considered as dose-limiting for RTH. Alopecia, muscles
fibrosis, self-limited transverse myelitis, and acute radiation
pneumonitis (ARP) can also be caused by radiation (Schreiber,
Meyers, Calhoun, and Talavera, 2013). Furthermore,
dysphagia and dysphonia was reported in 4.7% of cases in the
present study, and impaired taste sensation in 1.9% of cases
only. BRT seems to be ideally suited for the pediatric patient
when used alone or in combination with EBRT to achieve local
control. It can reduce the dose of radiation to normal tissues
and shortens the overall treatment time while maintaining a
comparable high rate of local control. Thus, reductions in
normal tissue doses decrease the probability of growth
deformity, CRTH interactions, and theoretically, the rate of
second tumor formation. BRT may also allow a reduction in
the EBRT dose required. The local control rates were effective,
but the operational difficulties to care children with BRT
sources make this approach restricted to few institutions.
However, the theoretical advantages of HBRT make this
treatment modality an interesting option to multidisciplinary
management of STS (Viani et al., 2008). Moreover, in the pre-
sent work, one patient only developed urinary complications
in the form of artificial bladder and urinary diversion due to
radical cystectomy for bladder mass. Furthermore, 2 cases
reported surgical complications in the current study. The 1St
one developed severe skin infection with skin necrosis that
necessitates repeated dressing and antibiotic therapy for 3
weeks. The 2nd case was subjected to excision of the lesion
with the related ribs with reconstruction using synthetic
mesh. She developed postoperative infection around the
mesh that necessitates second look operation to remove the
mesh 3 months later. But Guzik et al. reported no complica-
tions during the surgery as well as postoperative period and
also, BRT.
Patients at risk include those receiving cisplatin and/or
carboplatin for neuroblastoma, hepatoblastoma, osteosar-
coma, STS or germ-cell tumors. Cisplatin is known to cause
permanent, sensorineural hearing loss, which is mostly
bilateral, begins at high frequencies and progresses to involvet of STS.
Delayed toxicity No. %
Urinary complications: 1 0.9
Skin fibrosis 7 6.6
2ry Malignancy: 6 5.7
AML 2 1.9
Skin cancer 3 2.8
Thyroid cancer 1 0.9
Fig. 1 e Primary site of STS patients.
Fig. 3 e The presenting stage of STS patients.
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incidence varieswidely from 11 to 97% (Stohr et al.., 2005). Nitz
et al. reported 49.1% of children with hearing impairment. In
the present study, four (3.8%) patients developed ototoxicity
due to local irradiations, one of them with external ear pri-
mary tumor. This may be explained by differences in the
treatment modalities and in the populations under investi-
gation. In addition, to date, there is no agreement regarding
the definition of hearing impairment. This impedes compari-
sons between different studies (Stohr et al.., 2005). Cisplatin-
induced hearing loss has been reported to be enhanced with
increasing cumulative dose (Bokemeyer et al., 1998; Brock,
Bellman, Yeomans, Pinkerton, and Pritchard, 1991; Schell
et al., 1989), bolus administration (Reddel et al., 1982;
Vermorken, Kapteijn, Hart, and Pinedo, 1983), prior cranial
irradiation (Schell et al., 1989) and young age (Schell et al.,
1989; Stohr et al., 2005). In comparison, the newer platinum
compound carboplatin has been reported to be less ototoxic.
In a number of studies no, or only low, ototoxicity was iden-
tified (Stohr et al., 2004); although severe hearing loss may
occur after high-dose therapy (Parsons et al., 1998; Skinner,
2004). The severity of hearing loss is often graded according
to the Mu¨nster classification (Schmidt, Bartholom€aus,
Deuster, Heinecke, and Dinnesen, 2007), but also according
to the Brock grading system (Brock et al., 1991) and the ASHA
criteria (www.asha.org). These late effects of cisplatin and
carboplatin in the treatment of children have been well-
described (Brock et al., 1991; Schell et al., 1989; Stohr et al.,
2004). The effects in adult patients, however, have not been
adequately investigated (Nitz et al., 2013).
Since the beginning of its use, radiation inmedical practice
has raised concerns regarding the risk of inducing cancers in
treatment recipients (Kam, Anthony, and Shek, 2013). All
children who receive RTH as a component of treatment are atFig. 2 e Histological subtype of STS patients.risk for secondary radiation-inducedmalignancy. The average
latency period is 7 years, but the risk does not appear to
decline over time. Results from the Childhood Cancer Survivor
Study indicate a risk of 8% over 30 years for tumors excluding
nonmelanoma skin cancers and an additional 9% risk of skin
cancer (Arndt et al., 2012; Friedman, Whitton, and Leisenring,
2010; Ginsberg et al., 2010). In the present study the risk
reached 5.7% 7 years after the end of treatment. Long-term
follow-up of these patients is mandatory. Today, it is well
recognized that radiation can induce malignancy, and com-
mon examples include breast (female), thyroid, lung and
leukemia (Kam et al., 2013; Roychoudhuri, Evans, Robinson,
and Møller, 2004). RTH-induced bone tumor has also been
reported but the incidence is below 1% in 5 years after treat-
ment, but it is believed that the risk depends on the age at
which the patient receives the radiation (risk increases with
younger age), size of the radiation field and the dose of radi-
ation received. In children receiving total body irradiation, the
incidence can reach as high as 29%. The typical types of bone
tumors induced include benign osteochondroma and malig-
nant sarcoma, of which osteosarcoma is the most common.
As for other types of radiation-induced cancers, RTH-induced
sarcoma has a latent period ranging from a couple of years to
decades, with the mean lying between 10 and 20 years (Kam
et al., 2013). The site of cancer development usually lies on
the periphery of the radiation field (Davies, Sundaram, and
James, 2009; Kam et al., 2013). Furthermore, Kam et al. pre-
sent an elderly female with previous RTH for breast cancer, 30
years prior, subsequently developing a fibrosarcoma in the
spine. In the current study, no one patient developed sar-
comas as a 2ry malignancy, but patients developed AML (2
cases), skin cancer (3 cases) and thyroid cancer (1 case). Sec-
ondary cancer induction is dose dependent and tissue irradi-
ated with doses below 6 Gy is known to be especially
endangered to develop secondary cancer (Sterzing et al., 2009).
On the other hand, the risk of t-MDS/AML following EwingFig. 4 e Acute effects of radiotherapy.
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can reach 127-fold increased risk in one cohort study.
Furthermore, Bhatia et al. concluded that exposure to cyclo-
phosphamide at 20.4 g/m2 with doxorubicin at 375 mg/m2 (in
the absence of etoposide and ifosfamide) placed patients at a
risk of developing t-MDS/AML that was comparable with an
exposure to cyclophosphamide at 9.6 g/m2, doxorubicin at
375 mg/m2, ifosfamide at 90 g/m2, and etoposide at 5 g/m2.
Additionally, one study has demonstrated that short-term use
of hematopoietic cytokines, in particular, filgrastim in the
setting of intensive antileukemic therapy, may increase the
risk of t-MDS/AML (Bhatia et al., 2007).
Despite the advances in cure rates for children and ado-
lescents with these tumors, the long-term consequences of
aggressive CTH, RTH, and surgery can be substantial. Survi-
vors are much more likely than controls to have at least one,
and often multiple, chronic medical conditions (Arndt et al.,
2012). Finally, the current study concluded that there are
many early and late toxicity of multidisciplinarymanagement
of STS patients that need interference. It is hoped that during
the next decade we will discover which patients can have
therapy reduced and still have the same good outcome, and
new approaches with targeted agents and new surgical and
radio-therapeutic techniques will be developed for patients
with metastatic disease (Arndt et al., 2012). Therefore, recom-
mendation regarding prospective testing via audiometry for
patients treated with platinum derivative CTH. Further
studies are required to further elucidate the modulation of
hearing threshold improvement by a potential toxic synergy
between CTH and RTH and other ototoxic drugs, including
ototoxic antibiotics. Post-pubertal boys should be offered
semen cryopreservation before initiation of therapy. Cryo-
preservation of oocytes or embryos (the latter requires use of
donor sperm) is possible for post-pubertal females but may
delay treatment initiation. Experimental cryopreservation of
testicular or ovarian tissue has been reported in the literature
but is not a current standard of care. Future approaches
including radiation dose reduction, volume reduction or
application of new radiation technologies are needed.r e f e r e n c e s
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